New injection could help shed pounds in obesity trial

NCT ID NCT06728124

Ongoing Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 study tests an injection called GZR18 for weight loss in 630 adults who are obese or overweight with related health issues. Participants receive either the drug or a placebo, and researchers measure weight change over time. The goal is to see if GZR18 is safe and effective for helping people lose weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR18 injection
What this could lead to: If successful, this could provide a new medication option for significant weight loss in people with obesity or overweight.
What could go wrong: This is a Phase 3 trial, but results are not yet published. The drug may cause side effects or not work better than placebo. Long-term safety and effectiveness are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Beijing

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.